PL376147A1 - Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof - Google Patents

Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof

Info

Publication number
PL376147A1
PL376147A1 PL03376147A PL37614703A PL376147A1 PL 376147 A1 PL376147 A1 PL 376147A1 PL 03376147 A PL03376147 A PL 03376147A PL 37614703 A PL37614703 A PL 37614703A PL 376147 A1 PL376147 A1 PL 376147A1
Authority
PL
Poland
Prior art keywords
cystic fibrosis
protein inhibitors
fibrosis transmembrane
conductance regulator
transmembrane conductance
Prior art date
Application number
PL03376147A
Other languages
Polish (pl)
Inventor
Alan Verkman
Tonghui Ma
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/262,573 external-priority patent/US20040063695A1/en
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of PL376147A1 publication Critical patent/PL376147A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL03376147A 2002-09-30 2003-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof PL376147A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/262,573 US20040063695A1 (en) 2002-09-30 2002-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
US48025303P 2003-06-20 2003-06-20

Publications (1)

Publication Number Publication Date
PL376147A1 true PL376147A1 (en) 2005-12-27

Family

ID=32044981

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03376147A PL376147A1 (en) 2002-09-30 2003-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof

Country Status (13)

Country Link
EP (1) EP1549321A4 (en)
JP (1) JP4977319B2 (en)
KR (1) KR20050061501A (en)
CN (1) CN100356922C (en)
AP (1) AP2005003292A0 (en)
AU (1) AU2003277162C1 (en)
BR (1) BR0314943A (en)
CA (1) CA2500498C (en)
EA (1) EA009847B1 (en)
MX (1) MXPA05003366A (en)
NZ (1) NZ538809A (en)
PL (1) PL376147A1 (en)
WO (1) WO2004028480A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2659364T3 (en) 2006-04-07 2018-03-15 Vertex Pharmaceuticals Incorporated Conveyor modulators of the ATP binding cassette
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
EP2142498A2 (en) 2007-04-02 2010-01-13 Institute for Oneworld Health Cftr inhibitor compounds and uses thereof
JP5389030B2 (en) * 2007-08-24 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド Isothiazolopyridinone useful for the treatment of (especially) cystic fibrosis
SI2578571T1 (en) 2007-11-16 2016-01-29 Vertex Pharmaceuticals Incorporated Isoquinoline modulators of ATP-binding cassette transporters
WO2009073757A1 (en) 2007-12-07 2009-06-11 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US20110105565A1 (en) * 2008-03-25 2011-05-05 The Regents Of The University Of California Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator
EP2615085B1 (en) 2008-03-31 2015-08-26 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as CFTR modulators
WO2009131951A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
WO2009131957A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US20110237528A1 (en) * 2008-09-19 2011-09-29 Institute For Oneworld Health Compositions and methods comprising imidazole and triazole derivatives
US8343976B2 (en) 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
WO2011048070A1 (en) * 2009-10-20 2011-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of disorders of glucose homeostasis
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
EP2826776B1 (en) 2010-03-25 2020-11-25 Vertex Pharmaceuticals Incorporated Solid dispersion of amorphous form of (r)-1(2,2-difluorobenzo(d)(1,3)dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)-cyclopropanecarboxamide
CN102917692A (en) 2010-04-07 2013-02-06 弗特克斯药品有限公司 3-(6-(1-(2,2-Difluorobenzo[D][1,3]dioxol-5-yl)cyclopropylcarboxamido)-3-methylpyridine-2 -Pharmaceutical composition of benzoic acid and method of administration thereof
ES2579965T3 (en) 2010-04-07 2016-08-17 Vertex Pharmaceuticals Incorporated Solid forms of 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropane carboxamide) -3-methylpyridin-2-yl) benzoic
SG184987A1 (en) 2010-04-22 2012-11-29 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
JP2013536231A (en) 2010-08-23 2013-09-19 バーテックス ファーマシューティカルズ インコーポレイテッド (R) -1- (2,2-difluorobenzo [D] [1,3] dioxol-5-yl) -N- (1- (2,3-dihydroxypropyl) -6-fluoro-2- (1 -Hydroxy-2-methylpropan-2-yl) -1H-indol-5-yl) cyclopropanecarboxamide and its administration
CN102133402B (en) * 2011-03-24 2013-06-12 首都医科大学附属北京同仁医院 Application of cystic fibrosis transmembrane transduction regulating factor inhibitor to preparation of medicaments for treating diabetes
US9056862B2 (en) 2011-05-10 2015-06-16 National University Corporation Kobe University Thioxothiazolidine derivative having Ras function inhibitory effect
RU2640420C2 (en) 2011-11-08 2018-01-09 Вертекс Фармасьютикалз Инкорпорейтед Modulators of atp-binding cartridge transporters
HUE044676T2 (en) 2012-01-25 2019-11-28 Vertex Pharma Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
AR092857A1 (en) 2012-07-16 2015-05-06 Vertex Pharma PHARMACEUTICAL COMPOSITIONS OF (R) -1- (2,2-DIFLUOROBENZO [D] [1,3] DIOXOL-5-IL) -N- (1- (2,3-DIHYDROXIPROPIL) -6-FLUORO-2- ( 1-HYDROXI-2-METHYLPROPAN-2-IL) -1H-INDOL-5-IL) CYCLOPROPANCARBOXAMIDE AND ADMINISTRATION OF THE SAME
UA117464C2 (en) 2012-11-02 2018-08-10 Вертекс Фармасьютікалз Інкорпорейтед PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CFTR DISEASE-MEDIATED DISEASE REGULATOR
FR2999191B1 (en) 2012-12-12 2016-02-05 Lesaffre & Cie PROBIOTIC STRAINS FOR THE TREATMENT AND / OR PREVENTION OF DIARRHEA
UA124567C2 (en) 2014-04-15 2021-10-13 Вертекс Фармасьютикалз Інкорпорейтед PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF DISEASES MEDIATED BY CYCLE-SIDE REGULATOR OF TRANSMEMBRANE CONDUCTIVITY
NZ768373A (en) 2014-10-06 2024-03-22 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
CN104398509B (en) * 2014-11-13 2017-01-11 四川大学华西第二医院 Application of CFTR (cystic fibrosis transmembrane conductance regulator) inhibitor CFTRinh-172 in preparation of drug for prevention and treatment of leukemia cell mediated diseases
CN104788423B (en) * 2015-03-13 2016-10-26 成都理工大学 A kind of new cystic fibrosis transmembrane conductance regulator inhibitor
AU2016377782B2 (en) 2015-12-24 2021-07-29 The Regents Of The University Of California CFTR regulators and methods of use thereof
LT3551622T (en) 2016-12-09 2021-02-25 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2019018395A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN111757874B (en) 2017-12-08 2024-03-08 弗特克斯药品有限公司 Methods for preparing modulators of cystic fibrosis transmembrane conductance regulator
MX2021015406A (en) * 2019-06-12 2022-01-24 Univ California Methods of treating bile acid diarrhea.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96654A (en) * 1989-12-21 1995-06-29 Lilly Co Eli Hydroxybenzyl substituted sulfur containing heterocyclic derivatives their preparation and pharmaceutical compositions containing them
AU1090795A (en) * 1993-11-12 1995-05-29 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
US6423708B1 (en) * 1996-09-30 2002-07-23 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides
UA56185C2 (en) * 1996-09-30 2003-05-15 Пфайзер Інк. Aralkyl- and aralkylidene heterocyclic lactams and imids, a pharmaceutical composition and a treatment method
IL141456A0 (en) * 1998-08-21 2002-03-10 Viropharma Inc Rhodanine derivatives and pharmaceutical compositions containing the same
US6484397B1 (en) * 2000-07-11 2002-11-26 Corning Incorporated Method of assembling a catalytic converter for use in an internal combustion engine
US20020052396A1 (en) * 2001-04-23 2002-05-02 Bailey Thomas R. Compounds, compositions and methods for treating or preventing viral infections and associated diseases

Also Published As

Publication number Publication date
WO2004028480A3 (en) 2004-07-01
WO2004028480A2 (en) 2004-04-08
KR20050061501A (en) 2005-06-22
EA200500583A1 (en) 2005-12-29
NZ538809A (en) 2008-06-30
AU2003277162B2 (en) 2009-07-16
CA2500498C (en) 2012-08-21
AU2003277162A1 (en) 2004-04-19
CA2500498A1 (en) 2004-04-08
EP1549321A4 (en) 2007-05-23
BR0314943A (en) 2005-08-02
EA009847B1 (en) 2008-04-28
JP4977319B2 (en) 2012-07-18
AU2003277162C1 (en) 2009-12-24
CN100356922C (en) 2007-12-26
MXPA05003366A (en) 2005-10-05
AP2005003292A0 (en) 2005-06-30
CN1684686A (en) 2005-10-19
EP1549321A2 (en) 2005-07-06
JP2006503853A (en) 2006-02-02

Similar Documents

Publication Publication Date Title
AP2005003292A0 (en) Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
WO2004040000A9 (en) G protein coupled receptors and uses thereof
PL375447A1 (en) Protein kinase inhibitors and uses thereof
DK1495128T3 (en) Enhanced protein expression in Bacillus
EP1552002A4 (en) Aptamer-toxin molecules and methods for using same
AU2003270341A8 (en) Modified asialo-interferons and uses thereof
HUP0301063A3 (en) Benzoic-acid isononylesters and applying them
AU2003280084A8 (en) Protein arrays and uses thereof
AUPS238502A0 (en) Cystic echinococcosis protein and uses therefor
AU2003268023A8 (en) Protein modification and maintenance molecules
HK1079695A (en) Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
AU2002348834A8 (en) Method and system providing user mobility in a mobile-ip-network by means of a personal ip address
AU2003301112A1 (en) Hand and fingernail cleaning apparatus
AU2003239871A8 (en) Protein modification and maintenance molecules
AU2003280992A1 (en) Novel proteins and use thereof
AU2003291426A8 (en) Gp64-pseudotyped vectors and uses thereof
AU2003292774A1 (en) Novel proteins and use thereof
AU7080601A (en) Activation of the cystic fibrosis transmembrane conductance regulator chloride channel
AU2003260487A8 (en) Novel pancortin-pablo protein interactions and methods of use thereof
AU2003202650A1 (en) Cystic echinococcosis protein and uses therefor
AU2003249644A8 (en) Mutant p53 (delta126-132) protein and uses thereof
EP1549951A4 (en) Semaphorin-like proteins and methods of using same
AU2003270876A8 (en) Anti-hla assay and methods
AU2003258658A1 (en) Improved dna and proteins
AU2003263751A8 (en) Novel proteins and their uses

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)